Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:22:53.231Z.
Calculation as of: 2026-10-06T18:22:53.231Z.
Quote observation: 2026-10-06T18:15:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ef632b76806419539d367682e283305f5302e219c84c42b2c880863f64fefb48
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Shuttle Pharmaceuticals Holdings, Inc.
Market Cap
$2.40M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.49M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.31M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.55M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | $2.40M | N/A | N/A | N/A | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.39M | N/A | N/A | N/A | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.37M | N/A | N/A | N/A | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.47M | N/A | N/A | N/A | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.49M | N/A | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.31M | N/A | N/A | N/A | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.55M | N/A | N/A | N/A | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.62M | N/A | N/A | N/A | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.17M | N/A | 0.00% | 0.00% | 0.00% |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.17M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute